ICER's life year calculation gives Novartis wider pricing ballpark for SMA therapy

Based on the number of years of life it adds, spinal muscular atrophy therapy Zolgensma onasemnogene abeparvovec (AVXS-101) would be cost effective if priced under $1.5 million per year, according to an evidence report released Friday from the Institute for Clinical and Economic Review (ICER). The SMA candidate from Novartis AG (NYSE:NVS; SIX:NOVN) is under FDA review with a decision

Read the full 606 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE